Straits Times Index
3,308.80 +8.80 (+0.27%) Nikkei
38,626.72 -6.30 (-0.02%) Hang Seng
18,046.36 -288.96 (-1.58%) FTSE 100
8,272.46 +67.35 (+0.82%) Bitcoin USD
64,557.84 -841.29 (-1.29%) CMC Crypto 200
1,352.18 -30.48 (-2.20%)
FDMT Oct 2024 22.500 call
| Previous close | 6.36 |
| Open | 6.35 |
| Bid | 3.20 |
| Ask | 6.90 |
| Strike | 22.50 |
| Expiry date | 2024-10-18 |
| Day's range | 6.35 - 6.36 |
| Contract range | N/A |
| Volume | |
| Open interest | 1 |
GlobeNewswire4DMT to Present Initial Interim 24-week Landmark Analysis from the 4D-150 Phase 2 PRISM Population Extension Cohort in a Broad Wet AMD Population at ASRS and Host a Corporate Webcast
24-week landmark safety and clinical activity data for 45 patients enrolled in the Population Extension cohort expected to be presented (N=30 at 3E10 vg/eye)Clinical data will be presented by Raj K. Maturi, M.D., a Principal Investigator in the PRISM study, at the American Society of Retina Specialists (ASRS) Annual Scientific Meeting on July 17, 2024 at 8:49 a.m. CESTCompany to provide a high-level safety update on 4D-150 treated patients from PRISM and SPECTRA studies (N=139) Company to host w
- GlobeNewswire
4DMT Presents Injection-Free Subgroup Analyses from 4D-150 Phase 2 PRISM Randomized Dose Expansion Cohort in Wet AMD Patients with Severe Disease Activity & High Treatment Burden at the Clinical Trials at the Summit 2024 Meeting
Injection-free subgroup results demonstrated that a single intravitreal dose of 4D-150 without any supplemental anti-VEGF injections resulted in stable mean visual acuity that was equal to or higher than in the standard bimonthly aflibercept control group at all six timepoints through Week 24Single intravitreal 3E10 vg/eye dose resulted in sustained reduction and stabilization of mean central subfield thickness (CST) compared to aflibercept at all timepoints In the 3E10 vg/eye injection-free sub
- GlobeNewswire
4DMT Presents Positive Interim Data from Phase 1/2 AEROW Clinical Trial of Aerosolized 4D-710 for Modulator-Ineligible/-Intolerant Cystic Fibrosis at 47th European Cystic Fibrosis Conference
Clinically meaningful improvements in ppFEV1 at 12 months observed in 2 of 3 participants with mild to moderate baseline lung function impairment (ppFEV1 50-80%) and >6 months follow up Aerosolized 4D-710 was well tolerated at doses up to 1E15 vg (n=6)Dose-dependent and widespread 4D-710-mediated CFTR transgene RNA and protein expression observed in all lung biopsies from all participants evaluated to datePre-existing AAV immunity cross-reactive with A101 did not affect transgene expression, bio
